# Non-Ventilator Hospital-Acquired Pneumonia (NV-HAP) in the ICU: Incidence and Prevention \*Barbara Quinn, RN, ACNS-BC; Dian Baker, RN, PhD; Carol Parise, PhD Sutter Medical Center, Sacramento; California State University, Sacramento; Sutter Institute for Medical Research

### PURPOSE

•To determine incidence and significance of non-ventilator hospitalacquired pneumonia (NV-HAP) in the ICU setting.

•Ventilator-associated pneumonia (VAP) has been well-studied.

•Ventilator prevention bundles have dramatically reduced the incidence of VAP across the nation and in our institute.

•However, little is known about the incidence of NV-HAP in the ICU

# **BACKGROUND/SIGNIFICANCE**

•Currently, there are no requirements to monitor NV-HAP.

•Limited studies available indicate that NV-HAP is an emerging factor in prolonged hospital stays of 7-9 days, patient mortality of 19.8%, and increased cost of \$40,000.

•New studies by Esperatti (2010) and Davis (2012) indicate that VAP and NV-HAP share similar pathogens and mortality rates, and NV-HAP occurs more frequently than VAP.

•Hospital-acquired pneumonia is generally considered a preventable condition, and may be subject to loss of reimbursement in the future.

## METHOD

•This was a descriptive, quasi-experimental study using retrospective data to determine the incidence, demographics, and clinical factors of NV-HAP. •NV-HAP data were obtained from a large, urban hospital's electronic integrated medical management system.

•Inclusion criteria: all adult discharges between January 1, 2010 and December 31, 2010, with ICD-9 codes of pneumonia-not present on admission, AND meeting the Centers for Disease Control and Prevention's (CDC's) definition for HAP.

•NV-HAP were then attributed to either medical/surgical or ICU, based on date of clinical onset.

#### RESULTS

•A total of 24,482 patients and 94,247 patient days were eligible for study inclusion.

•There were 14,396 adult ICU days: 35 NV-HAP cases, with an infection rate of 2.43 per 1000 non-ventilated days.

•There were 79,851 adult medical/surgical days: 80 NV-HAP, cases, with an infection rate of 1.0 per 1000 patient days.

•The rate of VAP was 0.19 per ventilation day.

www.PosterPresentations.con

•Demographics and risk factors for NV-HAP were similar between groups. •Estimated cost of NV-HAP in ICU over the one year period:

• \$1.4 million, 280 extra days, 7 deaths.





# **PREVENTION OF NV-HAP**

•"Identify modifiable risk factors and develop programs to reduce the risk of pneumonia by changing those risk factors." (CDC, 2003) •Reducing pathogens in the mouth/throat is a simple, modifiable risk factor for pneumonia – we chose to start here.

# **IMPROVING ORAL CARE IN THE ICU**

- •Revised Oral Care Protocol to include non-ventilated patients.
- •Purchased therapeutic oral care tools.
- •Monthly data collection of oral care *process* and NV-HAP *outcome*.

"We are preventing pneumonia and saving lives, one clean mouth at a time." (HAPPI Team, 2012)

# **PREVENTION OF NV-HAP**

- Comprehensive oral care
- Oral care protocol that
- includes all patients.
- Swallow screens
- Tube feeding protocols
- Up in chair for meals
- Lung expansion
- Early mobilization
- Serum glucose in target
- range

**Prevent Hospital-Acquired** Pneumonia



and analysis.



# OUTCOMES

Incidence of NV-HAP in ICU

## ACKNOWLEDGEMENTS

•We appreciate the grant from Sage to help us with costs of data collection

•A special "thank you" to our ICU leaders and oral care champions: Tracy Chu, RN, Educator and Traci Sheesley, RN, ICU Director.

•We could not have made this much progress without the tireless efforts of our Hospital-Acquired Pneumonia Prevention Initiative (HAPPI) team and all our bedside nursing staff: you are making a difference for our patients!—thank you!



